- Home
- FGEN
FGEN
FibroGen Inc
as 07-26-2024 4:00pm EST
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The Company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 111.4M | IPO Year: | 2014 |
| Target Price: | $2.00 | AVG Volume (30 days): | 2.9M |
| Analyst Decision: | Sell | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.45 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.33 - $2.93 | Next Earning Date: | 08-05-2024 |
| Revenue: | $167,493,000 | Revenue Growth: | 44.30% |
| Revenue Growth (this year): | 3.84% | Revenue Growth (next year): | 1.35% |
Stock Insider Trading Activity of FibroGen Inc (FGEN)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Adib Deyaa | FGEN | Chief Medical Officer | Jun 12 '24 | Buy | $1.17 | 22,123 | $25,883.91 | 82,123 | SEC Form 4 |
| Wettig Thane | FGEN | CEO | Mar 7 '24 | Buy | $1.91 | 50,000 | $95,470.00 | 470,178 | SEC Form 4 |
Latest FibroGen Inc News
FGEN Breaking Stock News: Dive into FGEN Ticker-Specific Updates for Smart Investing
Simply Wall St.
a month ago
Favourable Signals For FibroGen: Numerous Insiders Acquired Stock
GlobeNewswire
a month ago
FibroGen to Host Part II of Virtual KOL Investor Event Series to Review FG-3246 Development Program in Metastatic Castration-Resistant Prostate Cancer on June 26, 2024
MT Newswires
2 months ago
FibroGen Investigational New Drug Application for Cancer Treatment Accepted by FDA; Regeneron Selected as Supplier
GlobeNewswire
2 months ago
FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen’s Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials
GlobeNewswire
2 months ago
FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors
GlobeNewswire
2 months ago
FibroGen to Present at Goldman Sachs 45th Annual Global Healthcare Conference
GlobeNewswire
2 months ago
FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology Annual Meeting
Simply Wall St.
3 months ago
FibroGen First Quarter 2024 Earnings: Beats Expectations
Compare FGEN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "FGEN FibroGen Inc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.